AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America. PAD patients are at high risk of myocardial infarction (MI), strokes, and other health complications. EUCLID is designed to evaluate cardiovascular (CV) event rate and safety in PAD patients. Ticagrelor is currently only approved for the prevention of cardiovascular events in patients with Acute Coronary Syndromes (ACS).
“The global burden of PAD is such that it necessitates further research of additional treatment options that may further reduce the risk of atherothrombotic CV events and CV death,” said William Hiatt, MD, Professor of Medicine, Division of Cardiology, University of Colorado School of Medicine. “The EUCLID study is an exciting clinical trial, as it may provide further clinical evidence regarding the role oral antiplatelets can play in reducing risk for patients with PAD.”
EUCLID is a randomised, double-blind, parallel group, multi-centre study evaluating the efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing the primary endpoint – a composite of CV death, MI or ischaemic stroke – in patients with PAD.
In the EUCLID study, symptomatic PAD patients who are 50 years of age or older will be randomised to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily. Now that plans to initiate the study have been finalised, the process of recruiting study investigators, clinical centres, and eventually patients will begin. Dr. Hiatt is the principal investigator for the EUCLID study, which is being conducted in partnership with the Duke Clinical Research Institute, an academic research organisation affiliated with the Duke University School of Medicine, and CPC Clinical Research, an academic research organisation affiliate of the University of Colorado.